Moderna Provides Business And Pipeline Updates At The Annual J.P. Morgan Healthcare Conference, Says Product Sales For 2023 Of Approximately $6.7B; U.S. Covid-19 Market Share Season To Date Increased To 48% In 2023, Up From 37% In 2022
Portfolio Pulse from Benzinga Newsdesk
Moderna provided updates at the J.P. Morgan Healthcare Conference, projecting 2023 product sales of around $6.7B. The company's U.S. COVID-19 market share has risen to 48% in 2023 from 37% in 2022. Moderna reaffirmed its 2024 sales forecast of $4B, with a return to sales growth expected in 2025 and a break-even point anticipated in 2026 due to new product launches and disciplined investment.
January 08, 2024 | 12:46 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Moderna anticipates 2023 product sales of $6.7B and has increased its U.S. COVID-19 market share to 48%. The company expects sales growth to resume in 2025 and to reach break-even in 2026.
The positive sales projection for 2023 and the increase in market share are likely to be viewed favorably by investors, potentially leading to a short-term increase in stock price. The reaffirmation of future sales growth and break-even expectations may further bolster investor confidence in the company's long-term strategy.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100